Agreement to Amend Series a-1 Convertible Preferred Sample Contracts

AGREEMENT TO AMEND SERIES A-1 CONVERTIBLE PREFERRED

Agreement to Amend Series a-1 Convertible Preferred • January 31st, 2020 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

• Contract Type
  Agreement to Amend Series a-1 Convertible Preferred
• Filed
  January 31st, 2020
• Company
  Outlook Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

This agreement to amend the Certificate of Designations (“COD”) setting forth the terms of the Series A-1 Convertible Preferred Stock, par value $0.01 per share (the “Series A-1 Preferred”) (this “Agreement”) of Outlook Therapeutics, Inc. (formerly known as Oncobiologics, Inc., the “Company”), dated as of January 27, 2020, by and between the Company and BioLexis Pte. Ltd. (formerly known as GMS Tenshi Holdings Pte. Limited, and together with or any of its permitted assigns, the “Holder”). Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to such terms in the COD (as defined below), whether defined therein or incorporated by reference.